A National Institute for Health and Care Excellence (NICE) – New guidance on the use of surrogate endpoints in cost-effectiveness analysis for use in Health Technology Assessment (HTA)
NICE collaborated with international HTA agencies from the US, Canada, Australia, the Netherlands, and Columbia to produce best practice recommendations for using surrogate endpoints in health economic models to guide HTA decisions. Surrogate endpoints are biomarkers or other intermediate outcomes that predict a treatment effect on a final clinical outcome and these outcomes are increasingly being used in licensing. The new guidance provides clarity and support for technology developers when using surrogate endpoints for analysing the cost-effectiveness of the drugs or devices they are developing. The white paper, available to download here, outlines how to select and check the surrogate endpoints, the selection of the longer-term benefits, and how to display them in evidence submissions. Please find further information here.
News reported on the 31st of January 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). A National Institute for Health and Care Excellence (NICE) – New guidance on the use of surrogate endpoints in cost-effectiveness analysis for use in Health Technology Assessment (HTA). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/13yeu





